Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iradimed (IRMD) EBIAT (2016 - 2025)

Iradimed (IRMD) has disclosed EBIAT for 13 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 25.17% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Dec 2025, up 16.88% year-over-year, with the annual reading at $22.5 million for FY2025, 16.88% up from the prior year.
  • EBIAT for Q4 2025 was $6.4 million at Iradimed, up from $5.6 million in the prior quarter.
  • The five-year high for EBIAT was $6.4 million in Q4 2025, with the low at $1.4 million in Q1 2021.
  • Average EBIAT over 5 years is $4.1 million, with a median of $4.2 million recorded in 2023.
  • Peak annual rise in EBIAT hit 510.7% in 2021, while the deepest fall reached 21.61% in 2021.
  • Over 5 years, EBIAT stood at $3.9 million in 2021, then dropped by 5.63% to $3.7 million in 2022, then grew by 23.58% to $4.5 million in 2023, then rose by 13.37% to $5.1 million in 2024, then grew by 25.17% to $6.4 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $6.4 million, $5.6 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.